Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Resource Type
Article
Authors
Kristeleit, Rebecca ; Lisyanskaya, Alla ; Fedenko, Alexander ; Dvorkin, Mikhail ; de Melo, Andreia Cristina ; Shparyk, Yaroslav ; Rakhmatullina, Irina ; Bondarenko, Igor ; Colombo, Nicoletta ; Svintsitskiy, Valentyn ; Biela, Luciano ; Nechaeva, Marina ; Lorusso, Domenica ; Scambia, Giovanni ; Cibula, David ; Póka, Róbert ; Oaknin, Ana ; Safra, Tamar ; Mackowiak-Matejczyk, Beata ; Ma, Ling ; Thomas, Daleen ; Lin, Kevin K ; McLachlan, Karen ; Goble, Sandra ; Oza, Amit M
Source
In The Lancet Oncology April 2022 23(4):465-478
Subject
Primary Research Articles
Language
ISSN
1470-2045